Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.

Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clin Infect Dis. 2022 09 10; 75(4):560-566.

View in: PubMed

subject areas

Alkynes
Anti-HIV Agents
Antitubercular Agents
Benzoxazines
Cyclopropanes
HIV Infections
HIV-1
Humans
Rifampin
Tuberculosis

authors with profiles

Susan Dorman